Natacha Bolaños

Natacha Bolaños

Head, Membership & Alliances

Lymphoma Coalition

 With a broad background as cancer rehabilitation specialist through exercise referral, Natacha is an EUPATI fellow with significant experience in patient advocacy and patient education in the field of cancer. Prior to joining Lymphoma Coalition in 2017, she had successfully held Patient and Public affairs roles in cancer charities in Spain since 2011. Natacha serves on multiple boards and committees for many organizations, including the EBMT Patient Advocacy Committee (Chair), EHA´s European Affairs Committee, ESMO Patient Advocacy Working Group, GoCART Coalition, Coalition for Reducing Bureaucracy in Clinical Trials, The Cellular Therapy Network (TerCel, now recalled RICORS-TERAV) and contributes to IMI and H2020 projects at European level, as Harmony Alliance, T2EVOLVE, and RESILIENCE. 

Natacha is a passionate bridge-builder, and a true believer in the power of cooperation. She sits on a number of scientific advisory boards, bringing a patient-oriented viewpoint to the research process, with the aim of improving clinical research feasibility by providing evidence-based knowledge of impacts on patients and serves as a critical reminder of the need for research focused on patient benefit and outcomes. She is used to work at a national, European and Global level with multi-stakeholders’ partnerships, educational groups, being deeply interested in removing barriers to access healthcare and to improving quality of life for patients. 

Natacha has contributed to Health Technology Appraisal (HTA) processes and is frequently invited to provide the patient perspective in different scenarios. At National level in Spain, Natacha has helped to launch the Spanish Society of Hospital Pharmacy (SEFH) Patient Advocacy Committee (PAC) being the first PAC within a Scientific Society, and is currently member of the Institutional Working Group of the Plan to Access Advanced Therapies in the National Health System: CAR therapies. 


Other speakers in 2022

Hugh Laverty


Hugh Laverty, PhD

Executive Director ad interim
The Innovative Health Initiative
Skip to content